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X-adrenoleukodystrophy (X-ALD,OMIM 300100) is an inherited neurodegenerative disorder. Due to defective peroxisomal beta-oxidation Very long chain fatty acids (VLCFA),  the biochemical markers of the disease,  accumulate in plasma, fibroblasts and different tissues [12,13,22,23 ].  
The mutated gene (ABCD1, Xq28),  encodes for the peroxisomal ABC half-transporter ALDP [15]  which  is supposed to associate, as a homo- or  heterodimer, with one of the other peroxisomal half-transporters encoded by  the gene ABCD2 , which presents the closest relation to ABCD1, and the other related genes ABCD3 and ABCD4 [6,7,8,11,21]. 
The function of ALDP and the related peroxisomal transporters  has not been completely elucidated, they should be involved in VLCFA peroxisomal metabolic pathways.
It has been demonstrated that   peroxisomal ABC half-transporters  can compensate the impaired function of ALDP and that different agonists are able to induce their expression, partially compensating the pathological abnormalities  of the disease such as enhancing  VLCFA beta-oxidation [1,2,3,4,5,8,16]. 
 These pharmacological approaches may represent important therapeutic   strategies for this pathology,   since the only available pharmacological treatment is represented so far by Lorenzo’s oil  [14,20].
In addition to adrenal cortex impairment, a certain percentage of patients may present with hypogonadism and alopecia, symptoms related to alteration in androgen metabolism. Testosterone is metabolized into dihydrotestosterone by 5-reductase (5-R), a key enzyme in steroid hormone metabolism. This metabolic step is an irreversible reaction. 5-R functionality and expression are differently modified in X-ALD, and in addition the metabolic products of the enzyme dihydrotestosterone (DHT)  and 5-androstan-3,17-diol (3-diol) affect lipid metabolism [17,19]. 
In the present study we evaluated the effect of the testosterone metabolite DHT and 3-diol on ABCD2 and ABCD3 expression in fibroblasts drawn from controls and from the two affected brothers exhibiting the same mutation but different clinical manifestations. Different responses to the androgens were observed in the two patients.
Skin fibroblasts were retrieved from controls and X-ALD patients monitored at the “Istituto Neurologico C. Besta”, Milan, Italy.  The diagnosis was based on plasma VLCFA evaluation, ABCD1 mutation  and clinical examination.  The controls were three healthy males. Written informed consent was obtained from both controls and patients or their guardians. X-ALD patients  were two brothers (ALD 1 and 2) with the same  ABCD1 mutation which consisted in  a deletion in exon 9. The clinical manifestations were different: ALD1 had the severe neurological form with onset at age 12, adrenocortical impairment  and had the biopsy done at age 19. ALD2 was asymptomatic, presented with alopecia and had the biopsy done at age 21. The ages of the controls ranged from 20-27 years.
 Skin specimens were grown as tissue cultures and maintained in Minimum Essential Medium (MEM) containing 10% FCS, non-essential amino acids, tricine, penicillin/streptomycin and maintained at 37°C, in 95% air and 5%CO2. Fibroblasts were incubated with steroid hormones at confluence(6-8th passage). 
The testosterone metabolite  DHT, 3-diol or the vehicle (ethanol, less than 0.1 %), were incubated, separately, in control and X-ALD fibroblasts, at a concentration of 10-6 M, for 6 hours. This length of time was sufficient  for gene activation and for the observation of  significant effects, since the action of androgens is very rapid and genes are activated in even shorter times [17].  
Total mRNA was extracted from X-ALD and controls fibroblasts as previously described [20]. Primers ( Qiagen Operon,Cologne, Germany) for Real-Time PCR were designed by human cDNA ABCD2 (GenBank Accession Number NM_005164) , ABCD3 (GenBank Accession Number NM_002858), and 18SrRNA (GenBank Accession Number NM_X03205) using the programs: Primer 3, Operon Toolkit and NCBI. ABCD2: forward primer 5’ CTTGCTGGATGAATGTA 3’; reverse primer 5’ TGTAATAAATGTGTGTGGTA 3’. ABCD3: forward primer 5’ CTC TGC CTG CTC CAC AA 3’; reverse primer 5’ TTG TTC TGT AAT GGT GGT TTT CC 3’. 18SrRNA: forward primer 5’ CGT TCT TAG TTG GTG GAG C 3’ ; reverse primer 5’ TAA GGG CAT CAC AGA CCT3’  . The Real-Time approach was used in all the experiments with SYBR Grenn (Sigma Chemical CO., St. Louis, MO, USA),using a “iCycler iQ Thermal Cycler” from Bio-rad (Hercules, CA, USA). Cycling conditions for ABCD2 begin with an initial hold a 94°C for 2’, followed by 50 cycles consisting of 94°C for 15’’, 51°C for 30’’ and 72°C for 30’’then 80 cycles with 60°C for 10’’.
 After a denaturation step at 94°C  for 2’, 50 cycles for ABCD3 were programed as follows: 15’’at 94°C, 75’’at the annealing temperature, and final extension at 60°C for 10’’.  The point at which amplification resulted in significant fluorescence above background was determined and noted as the thereshold cycle (CT  ). These CT data were then used to normalyze and calculate the fold difference between  gene standard 18SrRNA and the target gene (ABCD2 and ABCD3), according to the 2  -CT  method by Livak and Schmittgen [10] (PE Biosystem Sequence Detector User Bulletin 2). A melting  curve was performed in order to confirm the generation of a specific amplicon.
The fragments amplified by Real-Time PCR, were also visualized on a 3% agarose gel, product  length: 135 bp for ABCD2, 77 bp for ABCD3, and 170 bp for 18SrRNA.
Representative Real-Time PCR analyses for ABCD2, ABCD3 and the housekeeping gene 18S are shown in Fig.1. The melting curves and the fragments, amplified by Real-time PCR and visualized on a 3% agarose gel, confirmed the generation of a specific amplicon (Fig.2).   In untreated conditions the patients showed an upregulation versus the controls  which resulted significant only for ABCD2 mRNA abundance (Fig.3). When cells were stimulated with DHT or 3-diol, the patients responded differently:  ALD1 with a significant upregulation, whereas  ALD2 enhancement was very limited (Fig.4). The response for DHT was stronger than for 3-diol,  as a result of the potent androgen activities of DHT. The controls, treated with androgens in the same conditions, presented an upregulation which reached almost significance levels (data not shown).  ABCD3 mRNA abundance did not show any significant variations for both patients (Fig.3 ).  All the experiments were repeated more than three times  with different preparations. Statistical evaluation was performed by a two-way analysis of variance (ANOVA),  Tukey’s test for multiple comparison was applied.
The two patients presented the same deletion of ABCD1 gene in exon 9 but had relevant differences in the phenotypes and clinical manifestations of the disease. ALD1 had a severe neurological form, ALD2 did not show any symptoms at the age of the biopsy and for the following years. 
At present it is difficult to explain why the  fibroblasts from the two patients responded to the androgens in different ways. Despite the mutation ALD2 did not show the typical symptoms of the disease, and the  basal ABCD2 upregulation or in general  the functionality  of ABC half -transporters might have been adequate and in relation to the normal metabolism of this patient. Moreover,   ALD2 presented alopecia. This symptom might be related to 5-R overexpression which results  in positive effects on its metabolite  DHT, in particular on lipid metabolism, which is of great relevance in X-ALD [17]. 
The significant response of ALD1 to androgens suggests that androgen treatment may be proposed  in order to compensate the patient’s severe metabolic and functional alterations. 
The lack of correlation   between a given genotype and the phenotypes, observed  in the two patients, is a characteristic feature of  X-ALD, a disease with elevated heterogeneity  and without a clear relationship between genotype and phenotype [9,12].
Limited information is available on  the effect of steroid hormones on peroxisomal ABC half-transporters   and on the possible interactions between these metabolic pathways which require to be explored in future research. 
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Fig.1. Representative Real-Time PCR for  ABCD2, ABCD3 and the housekeeping gene 18S in X-ALD fibroblasts. The intercalating dye SYBR Green was used in all the experiments. 

Fig.2. Melting curves obtained for ABCD2, ABCD3 and the housekeeping gene 18S confirmed the generation of a specific amplicone. The fragments, amplified by Real-time PCR, were visualized on a 3% agarose gel.

Fig.3. Fold change  of ABCD2 and ABCD3 genes. The fold change, in  X-ALD versus. the controls (refered to as 1) in basal conditions, was calculated using the CT  method, as indicated in the text.  All the experiments were repeated at least three times  with different preparations.    The values are represented as mean and the error bars represent  S.E.M.    * P<0.01 was considered statistically significant versus. controls, according to Tukey’s test.

Fig.4. Fold induction of the  ABCD2 gene in X-ALD fibroblasts after treatment with DHT or 3-diol. All the experiments were repeated more than three times  with different preparations.   The values are represented as mean and the error bars represent  S.E.M.    
* P<0.01 was considered statistically significant versus. untreated conditions (vehicle), according to Tukey’s test.
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